DNTH - CIK 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$129.06M | -$78.18M | -$36.86M | -$29.07M | -$9.90M | -$64.02M |
| Capital expenditure | - | - | - | $314.00K | $1.26M | $400.00K |
| Investing cash flow | -$122.83M | -$286.81M | $20.25M | -$59.82M | -$33.00K | -$10.63M |
| Dividends paid | - | - | - | - | - |
Dianthus Therapeutics, Inc. /DE/ reported operating cash flow of -$129.06M for fiscal year 2025. That is down 65.1% from -$78.18M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$6.53M (FY 2016) to -$129.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $280.13M | $255.62M | $133.57M | $96.68M | $14.91M | $67.74M |